Amarna Therapeutics partners with NorthX Biologics to advance Nimvec™ AM510 gene therapy development
Mission
We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.
Latest Portfolio Company News
Latest Press Releases
Interim report Q3 2024
The interim report for the third quarter 2024 was published on Wednesday October 16 at 08:00 CEST.
Presentation: the same day at 14:00 CEST.